PHARMA
PHARMAPharmaceutical Hydrogenation Membrane in Netherlands
Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. The Netherlands is positioning itself as Europe's hydrogen gateway, with the Port of Rotterdam developing into a major hydrogen import and production hub.
Market Context
NetherlandsPolicy
H₂ Target
Cities
Industries
Ultra-Clean Hydrogen Source
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
GMP-Compatible On-Site Generation
On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.
Batch-Flexible Operation
Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.
Pharmaceutical Hydrogenation in Netherlands’s Hydrogen Market
The Netherlands is positioning itself as Europe's hydrogen gateway, with the Port of Rotterdam developing into a major hydrogen import and production hub. Dutch industrial clusters in chemicals, refining, and steel are among the first in Europe to commit to large-scale green hydrogen adoption. The proximity to the North Sea wind corridor further accelerates offshore wind-to-hydrogen projects.
For Dutch hydrogen projects centered around Rotterdam, IONZERA provides a cost-competitive alternative to the Belgian-produced Zirfon. With 3x lower resistance, IONZERA improves the economics of large-scale electrolysis projects crucial for the Netherlands' hydrogen hub ambitions.
Lower Resistance
Thinner Profile
PERFORMANCE ADVANTAGE
Why IONZERA for Pharmaceutical Hydrogenation in Netherlands
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
Shipping & Logistics
Air freight from India in 5-7 business days. Proximity to Belgian Zirfon manufacturing allows direct performance and pricing comparison.
Area Resistance
3x LOWERThickness
20% THINNERPharmaceutical Hydrogenation Membrane in Netherlands Cities
Frequently Asked Questions
Why choose IONZERA for pharmaceutical hydrogenation in Netherlands?
IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in Netherlands. For Dutch hydrogen projects centered around Rotterdam, IONZERA provides a cost-competitive alternative to the Belgian-produced Zirfon.
Can IONZERA support large-scale Rotterdam hydrogen hub projects?
Yes. IONZERA is designed for both pilot and MW-scale AWE systems. Its 3x lower resistance improves stack efficiency at scale, and G-Hexa can supply volume quantities for large Dutch hydrogen infrastructure projects.
How does IONZERA compare to locally available Zirfon membranes?
IONZERA delivers 3x lower area resistance (0.09-0.1 vs 0.30 ohm-cm2), is 20% thinner (350-410 vs 500 um), and uses a mesh-free design vs Zirfon's PPS mesh reinforcement. These advantages translate to more efficient electrolysis at lower stack costs.
EXPLORE MORE
Request Pharmaceutical Hydrogenation Samples for Netherlands
Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for Netherlands-based projects.
Request Sample